Preferred Label : Ingitamig;
NCIt synonyms : Tri-specific NK Cell Engager Therapeutic Agent CC-92328; TriNKET CC-92328;
NCIt definition : A tri-specific natural killer (NK) cell engager targeting the tumor-associated antigen
(TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily
member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities.
Upon administration, ingitamig targets and binds to BCMA on tumor cells and simultaneously
binds to NK cells via the receptors CD16 and NKG2D (natural killer group 2D; killer
cell lectin-like receptor K1; KLRK1), thereby bringing BCMA-expressing tumor cells
and NK cells together. This activates NK cells and results in the selective NK cell-mediated
killing of BCMA-expressing tumor cells. In addition, the NK cells activate T- and
B-cells, and enhance a cytotoxic T-lymphocyte (CTL)-mediated immune response against
BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor
superfamily (TNFRSF) that binds to both a proliferation-inducing ligand (APRIL; TNFSF13)
and B-cell activating factor (BAFF; TNFSF13B), plays a key role in plasma cell survival.
BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma
cells.;
UNII : 6R6GWJ8GDZ;
Molecule name : CC-92328; CC 92328; BMS 986392; DF-3001; DF 3001; BMS-986392;
NCI Metathesaurus CUI : CL1798737;
Origin ID : C190202;
UMLS CUI : C5783561;
Semantic type(s)
- concept_is_in_subset
- has_target
